$Aadi Biosciences (AADI.US)$
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
Aadi Bioscience (NASDAQ: AADI) has announced the halt of its PRECISION1 trial for nab-sirolimus in solid tumors with TSC1 or TSC2 alterations due to unlikely regulatory approval. The company will now focus on its FYARRO® commercial business for PEComa and conduct a strategic review. To extend cash runway into at least 2H 2026, Aadi will:
Adjust ongoing Phase 2 trials
Reduce R&D headcount by 80%
Pause...

$Aadi Biosciences (AADI.US)$
NEWS
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
Aadi Bioscience presented new nonclinical data at the ASCO Annual Meeting showing that nab-sirolimus achieved higher intratumoral drug concentrations, stronger mTOR target inhibition, and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft model. These findings suppo...

$Aadi Biosciences (AADI.US)$ get in now at 2 and get out around 2.5pt. Not fin advice

🚨⚡️🚨⚡️🚨 3/4/2024
$Envoy Medical (COCH.US)$ $CXApp (CXAI.US)$ $Aadi Biosciences (AADI.US)$ $Curo集團 (CURO.US)$ $BigBear.ai Holdings (BBAI.US)$ $菲斯克 (FSR.US)$ $Ainos (AIMD.US)$
📊⚡️📊